HC Wainwright & Co. increased the price target for Pasithea Therapeutics to $4.00 from $3.00.

Nov 14, 2026, 9:09 AM ETOpinionRead the original at moomoo.com

Good for KTTA

HC Wainwright raised its target and kept its buy recommendation, a favorable signal for KTTA. The story gives no PAS-004 results, so this reflects the firm's view rather than a reported change in the company's progress.

KTTA · Pasithea Therapeutics Corp.

AI read · Good for KTTA

The AI's read

A higher share target shows HC Wainwright now sees more room for KTTA shares to rise. The story links the change to PAS-004 clinical developments but gives no details about them. The favorable signal comes from the firm's view, not a reported change in the company's results.

Get alerts for KTTA

Follow Pasithea Therapeutics Corp. (KTTA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KTTA

Free on the App Store and Google Play, or on the web.